Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy

Lise L. Gluud*, Rebecca Jeyaraj†, Marsha Y. Morgan†

*Gastrounit, Copenhagen University Hospital Hvidovre, Kettegaard Alle 30, 2650 Hvidovre Denmark and †UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, Hampstead, London, NW3 2PF, UK

Randomised clinical trials and systematic reviews of research findings can provide high-quality evidence for decision-making in the management of patients with hepatic encephalopathy. A large number of clinical trials have been undertaken, over the last 50 years, relative to the prevention and treatment of this condition. However, changes have been made, during this time, in the classification of hepatic encephalopathy, diagnostic criteria and assessment measures. These temporally based changes and the consequent lack of standardisation make it difficult to compare interventions and to evaluate their comparative efficacy and safety. While some consensus has been reached in relation to the diagnostic evaluation, classification and monitoring of patients in clinical trials, there is less surety about the choice of clinical endpoints. These outcome measures should be universally applicable, easily measured and clinically relevant. This article reviews the current recommendations regarding outcome selection and outlines some of the potential problems and pitfalls inherent in clinical trial evaluating interventions for the management of hepatic encephalopathy. (J CLIN EXP HEPATOL 2019;9:354–361)

Hepatic encephalopathy is the term used to describe the spectrum of neuropsychiatric change that can occur in people with liver insufficiency and/or portal systemic shunting.¹ Clinically apparent or overt hepatic encephalopathy manifests as a variety of mental and motor disorders.² It may develop spontaneously over a period of hours or days, although in the majority of patients an obvious precipitating factor, such as, treatment non-compliance, dehydration, constipation, infection or gastrointestinal bleeding, is identified.³ Episodes may recur; less frequently the neuropsychiatric abnormalities persist.² *Minimal* hepatic encephalopathy is the term used to describe the neuropsychiatric status of people with liver disease who appear clinically normal but show neuropsychometric/neurophysiological abnormalities, when tested.²

Hepatic encephalopathy is a common and debilitating complication of cirrhosis. Between 10% and 14% of people

with cirrhosis have overt hepatic encephalopathy when they are first diagnosed with liver disease.⁴ In people with decompensated cirrhosis, the prevalence of overt hepatic encephalopathy, at presentation, is around 20 to 30%.^{5–8} In people with cirrhosis who have no evidence of neuropsychiatric impairment, the risk of developing an episode of overt hepatic encephalopathy, within 5 years of presentation, varies from 5% to 25%, depending on the presence or absence of other risk factors; the cumulative incidence of overt hepatic encephalopathy is as high as 40%.^{9,10} The prevalence of minimal hepatic encephalopathy is likely to exceed 50% in people with previous overt hepatic encephalopathy.^{11–13}

The presence of hepatic encephalopathy, whether minimal or overt, is associated with significant impairment in the performance of complex tasks, such as driving,^{14,15} and detrimental effects on quality of life¹⁶ and safety.¹⁷ In addition, the presence of overt hepatic encephalopathy in people awaiting liver transplantation has a detrimental effect on neurocognitive function posttransplantation¹⁸ and on survival.^{19–22} The 1-year survival rate in people who have hepatic encephalopathy at presentation is 36%, with a 5-year survival rate of 15%,²² while the survival probability after a first episode of hepatic encephalopathy is 42% at 1 year falling to 23% at 3 years.¹⁹ Overt hepatic encephalopathy also poses a substantial burden for the carers of affected people²³ and a significant financial burden on health-care systems.^{24,25}

Given that hepatic encephalopathy is such a common and debilitating complication of cirrhosis, the

Keywords: cirrhosis, mortality, risk-benefit, serious adverse events, surrogate markers

Received: 12.3.2018; **Accepted:** 6.2.2019; **Available online** 15 February 2019

Address for correspondence: Marsha Y. Morgan, Tel.: +44 0 207 433 2873

E-mail: marsha.morgan@ucl.ac.uk

Abbreviations: CFF: Critical Flicker Fusion Frequency; EEG: Electroencephalogram; EQ-5D: European Quality of Life-5 Dimensions; ICMJE: International Committee of Medical Journal Editors; ICT: Inhibitory Control Test; ICTRP: International Clinical Trials Registry Platform; PHES: Psychometric Hepatic Encephalopathy Score; WHO: World Health Organisation

<https://doi.org/10.1016/j.jceh.2019.02.004>

identification of effective and safe interventions for its management is essential.

EVIDENCE-BASED APPROACH TO THE CONDUCT OF RANDOMISED CLINICAL TRIALS

The emphasis on evidence-based practice in healthcare has stimulated the undertaking of randomised clinical trials evaluating health-care interventions.^{26–28} The results from these trials may have a considerable influence on clinical practice and determine the interventions offered to patients. Guidelines exist to ensure that the conduct of randomised clinical trials is optimised by focusing on research design and the procedures associated with internal validity and reporting.^{29,30} Meta-epidemiological studies have identified a number of design features associated with exaggerated estimates of the effects of interventions, including inadequate/unclear sequence generation and allocation concealment; bias is greatest in trials with subjective rather than objective outcomes.^{31,32}

Reviews of randomised clinical trials evaluating interventions in patients with cirrhosis have identified a number of potential methodological problems.^{33–35} These include potential biases associated with the allocation of interventions and blinding as well as the extent to which trials allowed generalisation of results. However, to date, much less attention has been paid to the importance of the selection, definition and reporting of trial endpoints; these are key determinants of the quality of the trial and hence the validity of the inferences that can be drawn from the outcomes. The lack of standardised and validated common outcome measures, which are meaningful for patients and health-care professionals, is an important obstacle in assessing interventions, determining their external validity and facilitating inter-intervention comparisons.

TRIAL ENDPOINTS FOR INTERVENTIONS IN HEPATIC ENCEPHALOPATHY

One of the most important considerations in designing any clinical trial is the choice of outcome measures.³⁶ The selection of the ‘primary endpoints’ has a considerable effect on the reliability of any trial designed to evaluate the benefit-to-risk profile of interventions.³⁶ Primary endpoints should be clinically meaningful measures of how patients feel, function and survive.³⁶ They should be readily measurable and interpretable and should be sensitive to the effects of the intervention. Above all, they should evaluate those measures which are of greatest significance and relevance to the patient’s condition and its treatment.

The selection of endpoints in trials for the prevention and treatment of hepatic encephalopathy is difficult, not

least because the pathophysiology of hepatic encephalopathy is complex and remains poorly understood.^{37,38} Further, patients with cirrhosis exhibit a spectrum of neuropsychiatric change, and this may be reflected in the relative importance of trial endpoints, e.g., changes in mental status are of prime importance in trials involving patients with overt hepatic encephalopathy but are generally not as relevant in patients with minimal hepatic encephalopathy, who are, by definition, clinically unimpaired. Patients with cirrhosis also exhibit considerable phenotypic heterogeneity relative to the aetiology and severity of their liver disease, and often have multiple comorbidities; these factors may independently affect outcomes and so must be factored into the trial design and controls exercised accordingly.

At present, the variables which provide the best primary endpoints, in trials assessing interventions in hepatic encephalopathy, are mortality, hepatic encephalopathy, serious adverse events, such as hospitalisations for the complications of cirrhosis, and health-related quality of life.

Many outcome measures used in clinical trial do not qualify as ‘clinically meaningful endpoints’ but are included as surrogate endpoints. Ideally, these surrogates should predict achievement of important effects on clinically meaningful endpoints. However, this is often not the case. Nevertheless, surrogate endpoints are commonly used as they allow performance of randomised clinical trials that are generally smaller in size, shorter in duration and tend to cost less. However, they provide more limited information on efficacy and less reliable assurances about safety, given that they are based on smaller safety data sets. Clinicians should be cautious when interpreting the results of trials which employ surrogate endpoints as primary outcome measures, particularly when determining whether interventions should be used in clinical practice.

Currently, there are no accepted, validated surrogate endpoints that can be translated into clinically useful outcomes in trials of interventions in hepatic encephalopathy. However, as there is no gold standard for the diagnosis of hepatic encephalopathy, trials, in this field, tend to employ composite endpoints, e.g., an assessment of mental status together with a measure of psychometric performance. However, the interpretability of composite endpoints is greatly influenced by the relative weighting of the included components, and this is often ignored.

Mortality

Mortality should be routinely documented, in randomised clinical trials, as an efficacy and/or safety outcome.^{10,39} It is an objective outcome and is, therefore, free of variability. Previous meta-epidemiological studies have found that mortality is less susceptible to bias in comparison to other outcomes.^{31,32} In addition, mortality has high internal

validity as survival is significantly associated with the presence of hepatic encephalopathy.^{19–21} Thus, it is likely that interventions which ameliorate hepatic encephalopathy would also influence survival.

Patients with cirrhosis may die as a result of complications of their liver disease; as a result of preexisting comorbidities; or as a result of an incidental event. These deaths are encompassed in an assessment of ‘all-cause mortality’, which can be ascertained without the need for adjudication. The relative importance of this endpoint for assessing the efficacy and safety of interventions varies depending on the severity of the hepatic encephalopathy and the duration of follow-up. Thus, all-cause mortality is an important endpoint in the evaluation of interventions in patients with acute overt hepatic encephalopathy, where the risk of death is high. However, in many of these trials, the follow-up period equates to the treatment period, which tends to be short; hence an effect on mortality could be overlooked and hence underestimated. All-cause mortality is also an important endpoint in the assessment of interventions in patients with chronic hepatic encephalopathy, where the period of follow-up tends to be more prolonged. All-cause mortality is not, however, a sensitive outcome measure in trials evaluating interventions in minimal hepatic encephalopathy or for the prevention of hepatic encephalopathy. The use of insensitive endpoints might preclude a fair assessment of the effectiveness of an intervention or possibly result in the prolongation of trials of ineffective interventions.

Additional information, of clinical, scientific and regulatory importance, may be obtained by examining disease-specific mortality; unlike all-cause mortality, the ascription of liver-related mortality may need adjudication. The primary cause of death should be defined as the underlying disease (or injury) that initiated the train of events resulting in death; in the case of certain complications of cirrhosis, such as variceal haemorrhage, spontaneous bacterial peritonitis, hepatorenal syndrome and hepatic encephalopathy, the primary cause of death is clearly liver-related. However, in some instances, it may be very difficult to ascribe a primary cause; for example, when death results from aspiration pneumonia developing as a complication of a variceal bleed.

Hepatic Encephalopathy

There is no gold standard test for the diagnosis of this syndrome. Rather, there are a number of individual techniques, which access different aspects of cerebral function, that can be used either singly or in combination, as surrogate endpoints. In practice, any measure with a proven relationship with the behavioural, prognostic and, possibly, pathophysiological features of this syndrome can be used as such.^{10,40,41}

The key requisites for any test or test system are: (i) they have been validated for use in this patient population, (ii)

appropriate normative data are available and (iii) controls can be exercised for any associated comorbidities. As the condition affects several components of cognitive functioning, not necessarily all to the same degree, use of more than one assessment technique is advised (Table 1). The available guidelines for testing are only loosely prescriptive but do distinguish between testing in clinical and research settings.^{1,10} In practice, the selection of assessment tools will be determined largely by factors such as simplicity of use, accessibility and cost.

In trials of interventions in patients with overt hepatic encephalopathy, mental status is often evaluated using the West Haven Criteria,⁴² while levels of consciousness are assessed using the Glasgow Coma Score.⁴⁴ (Tables 2 and 3) The detection of the lower grades of change in mental status is often difficult, and the interobserver reproducibility is relatively poor. Thus, it might be advisable to restrict trial participation to those patients with Grade II change or above. The assessment of mental status, given its subjectivity, is not considered sufficiently robust to provide a primary endpoint for interventional trials in these patients. Thus, it is recommended that at least 2 validated tests are also included (Table 1). Patients with minimal hepatic encephalopathy do not, by definition, exhibit clinically detectable neuropsychiatric change; thus, interventional trials, in this patient population, rely even more heavily on the use of surrogate endpoints, which need to be robust and rigorously applied (Table 1).

In view of the difficulties perceived in detecting Grade 1 overt hepatic encephalopathy, it has been suggested that patients with minimal and Grade I change should be combined into a single group—‘covert’ hepatic encephalopathy.^{1,10} However, it is unclear how informative or valuable this approach is likely to be in assessing efficacy and safety in interventional trials. Indeed, it has

Table 1 Guidelines for the Diagnosis of Hepatic Encephalopathy in Patients with Cirrhosis.^{1,10}

Clinical setting or single-centre trial
1 Detailed clinical assessment to identify or exclude clinical change
2 At least 2 validated tests of which one should be more widely accepted so as to serve as a comparator, e.g. PHES
Multicentre-trial
1 Detailed clinical assessment to identify or exclude clinical change
2 At least 2 validated tests preferably the PHES plus one test from either of the following 2 groups:
- ICT, Stroop, Scan
- EEG or CFF

PHES, psychometric hepatic encephalopathy score; ICT, inhibitory control test; EEG, electroencephalogram; CFF, critical flicker fusion frequency.

Table 2 West Haven Criteria for Grading Mental Status in Patients with Cirrhosis.^a

Grade	Features
0	No abnormality detected
I	Trivial lack of awareness Euphoria or anxiety Shortened attention span Impairment of addition or subtraction
II	Lethargy or apathy Disorientation for time Obvious personality change Inappropriate behaviour
III	Somnolence to semi-stupor Responsive to stimuli Confused Gross disorientation Bizarre behaviour
IV	Coma, unable to test mental state

^aBased on the description of the mental state alterations in hepatic encephalopathy originally proposed by Conn et al⁴² as a modification of the Parsons-Smith criteria.⁴³

Table 3 Glasgow Coma Scale⁴⁴ for Grading Level of Consciousness.

Variable	Points	Feature
Eye	1	Does not open eyes
	2	Opens eyes in response to painful stimuli
	3	Opens eyes in response to voice
	4	Opens eyes spontaneously
Verbal	Not testable	Makes no sounds
	1	Incomprehensible sounds
	2	Utters incoherent words
	3	Confused, disoriented
Motor	4	Oriented, converses normally
	1	Makes no movements
	2	Extension to painful stimuli
	3	Abnormal flexion to painful stimuli
	4	Flexion/withdrawal to painful stimuli
	5	Localises to painful stimuli
	6	Obeys commands

been shown that patients classified as such behave, when tested, as 2 relatively independent groups.^{45,46}

Surrogate Endpoints for Hepatic Encephalopathy

A number of surrogate endpoints are available.

Psychometric Tests: Patients with hepatic encephalopathy show a range of neuropsychometric abnormalities. In consequence, a large number of psychometric tests have been evaluated in this patient population, but none is specific for the diagnosis of this condition. For this reason, test

batteries are generally more reliable than single tests and tend to be more strongly correlated with functional status. Of these test batteries, the best known and most extensively validated is the Psychometric Hepatic Encephalopathy Score (PHES),^{47,48} which comprises of 5 paper and pencil tests. The PHES test battery is currently recommended as the 'best clinical standard' for the assessment of psychometric status in patients with cirrhosis.¹ Test scores need to be normalised for a number of confounding variables; normative data are available in several countries. Computer-based psychometric tests may allow a more precise quantification of reaction times and more refined testing, but require further validation.⁴⁹

Critical Flicker Fusion Frequency: Critical flicker fusion frequency is a test based on the perception of light as flickering or fused as its frequency changes.⁵⁰ It assesses visual discrimination ability and general arousal. Results have diagnostic and predictive validity.⁵¹⁻⁵³ There are some differential effects in relation to age and the aetiology of the underlying liver disease.⁵⁰ Testing requires intact binocular vision and, for some commercial equipment, normal colour vision.

Inhibitory Control Test: The inhibitory control test is a computerised, chronometric test of attention and response inhibition. It can be freely downloaded from www.hecme.tv. Patients are shown a series of random letters and are asked to respond to predefined sequences designated as targets or lures. Low-target and high-lure responses indicate poor performance.⁵⁴ The test has greater diagnostic utility if the number of lures (inhibitory ability) is adjusted by the target accuracy (attention ability).⁵⁵ Results have diagnostic and predictive validity.⁵⁵ The test data need to be adjusted for age and education, and there is a learning effect. The test is considered difficult to perform by both healthy subjects and patients with cirrhosis, which potentially limits its usefulness.⁵⁶

Stroop Test: The Stroop test is based on differences in recognition reaction times to colour stimuli depending on how they are presented. The test evaluates psychomotor speed and cognitive flexibility. Performance on the Stroop test is affected by a number of confounders including age, sex and education; population normative data are available in the United States.⁵⁷ A smartphone application (EncephalApp_Stroop; www.encephalapp.com) is available.

Scan Test: The Scan package or Sternberg test is a computerised test system based on a digit recognition memory task. It assesses cognitive attention, psychomotor speed and working memory at 3 levels of increasing difficulty. Scan software provides a Z score based on reaction times and errors, corrected for age and education; there is likely to be a learning effect. There is relatively little information on the diagnostic and predictive validity of the Scan package but some promising early results.⁵⁸

Electroencephalogram: The electroencephalogram (EEG) reflects cortical neuronal activity. The recording procedure does not require patient co-operation and is not subject to learning effects—problems which beset other assessment methods.⁵⁹ The main EEG characteristic of this condition is progressive slowing of the mean frequency but this is not specific as similar changes can be observed in other metabolic and drug-induced encephalopathies.⁶⁰ In interventional trials in hepatic encephalopathy, spectral analysis of the recordings is likely to be more informative.⁶¹ Further advances in EEG technology are likely to provide better quantifiable and more informative data. The advent of low-cost, wireless headsets might encourage more widespread use of this technique.⁶²

Other Surrogate Endpoints: At present, there are no validated biomarkers that can be used as surrogate endpoints in interventional trials in hepatic encephalopathy. Ammonia plays a key role in the pathogenesis of this syndrome,^{37,38} and treatment is generally directed at reducing circulating ammonia levels. However, blood ammonia concentrations do not correlate directly with clinical status or with psychometric/neurophysiological outcomes.^{63,64} Nevertheless, blood ammonia concentrations are frequently used as an endpoint in interventional trials in this field; caution must be exercised when interpreting the results.

Serious Adverse Events

Serious adverse events are defined as any untoward medical occurrence that leads to death, is life threatening, requires hospitalisation or prolongation of hospitalisation or results in persistent or significant disability.⁶⁵ Serious adverse events should be one of the primary endpoint in any interventional trial.

Health-Related Quality of Life and Aspects of Daily Functioning

The presence of hepatic encephalopathy, whether minimal or overt, has a detrimental effect on patients' health-related quality of life.¹⁶ This variable should be included as a primary outcome variable in some, but not all, intervention trials in hepatic encephalopathy. Thus, its inclusion in the short-term trials undertaken in patients with acute hepatic encephalopathy is unlikely to provide useful information. However, its inclusion in interventional trials in minimal, recurrent and persistent hepatic encephalopathy is likely to be particularly informative.

Health-related quality of life can be assessed using a number of generic tools such as the Sickness Impact Profile⁶⁶ and the 36-item short-form questionnaire,⁶⁷ or the more specific Chronic Liver Disease Questionnaire.⁶⁸ These questionnaires have their merits but are not easily applied. In contrast, the European Quality of Life-5 Di-

mensions (EQ-5D)⁶⁹ questionnaire and visual analogue scale, while not disease-specific, are standardised; the EQ-5D is easy to complete and produces a single index value, which can be compared against country-specific, societal norms.

Patients with hepatic encephalopathy have difficulty performing complex tasks such as driving^{14,15} and are prone to injuries because their risk of falls is increased.¹⁷ These factors will impinge on their quality of life and will, to some extent, be captured within this assessment.

REGISTRATION AND REPORTING OF TRIAL ENDPOINTS

Clinical trials should, in line with the policy of the World Health Organisation (WHO) and the International Committee of Medical Journal Editors (ICMJE), be registered in a publicly owned, publicly accessible registry and should satisfy a minimum data set.^{70,71} This policy requires that any clinical trial initiated after July 1, 2005, irrespective of the assessed intervention, should be prospectively registered as a prerequisite for manuscript submission.^{70,71} Trial registration should take place before or at the time of enrolment of the first participant in the trial. This should discourage the changing, omitting or introduction of endpoints identified after preliminary examination of the clinical trial results.

There are a large number of primary trial registries, most regional based. Collective information from these registries can be accessed *via* 2 main, publicly available, web-based platforms *viz*, ClinicalTrials.gov, established by the Department of Health and Human Services through the National Institutes of Health and the WHO International Clinical Trials Registry Platform (ICTRP); they provide information on registered trials worldwide.

Although these requirements are well publicised, they are frequently contravened. Thus, a review of trial registrations for gastrointestinal interventions in ClinicalTrials.gov found that many were registered inadequately, often lacking information on basic methodology.⁷² Several trials which were subsequently published in journals that subscribed to the ICTRP policy were registered *post hoc*. In others, there were discrepancies between the registered trial endpoints and those detailed in the published paper. Likewise, systematic reviews evaluating interventions in patients with cirrhosis have found that several of the included trials were not registered, were registered after the inclusion of the first participant or reported endpoints which differed from those in the registered protocols.^{33–35}

Even journals that strongly support the ICMJE policy on trial registration are not adequately enforcing it. Thus, in a review of trials published in the 6 highest impact general medicine journals, almost a third were registered

retrospectively, 10% were registered after an assessment of the primary endpoints could have been made.⁷³

A lack of consistent registration and reporting of trials is likely to introduce reporting bias which could inflate the estimated benefits of an intervention.⁷³ More rigorous enforcement of the WHO and ICMJE policy on trial registration is clearly needed.

CONCLUSION

The conduct and reporting of high-quality randomised clinical trials is essential to ensure evidence-based clinical practice. In the field of hepatic encephalopathy, the assessment of interventions should include clinically relevant endpoints such as mortality, hepatic encephalopathy, serious adverse events and health-related quality of life. These endpoints should be standardised to facilitate comparison between different interventions, settings and patient populations. The lack of a gold standard for the diagnosis of hepatic encephalopathy means that surrogate endpoints need to be employed, but none is validated. In consequence, the use of composite endpoints is recommended.

CONFLICTS OF INTEREST

L.L.G. was member of advisory board and received travel expenses from Novo Nordisk, presentations from Norgine and Eli Lilly and presentations and research funding from Alexion. R.J. and M.Y.M. have none to declare.

REFERENCES

- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. *Hepatology*. 2014; 60(2):715–735.
- Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. *Hepatology*. 2002;35(3):716–721.
- Pantham G, Post A, Venkat D, Einstadter D, Mullen KD. A new look at precipitants of overt hepatic encephalopathy in cirrhosis. *Dig Dis Sci*. 2017;62(8):2166–2173.
- Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. *BMJ*. 1981;282(6260):263–266.
- D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. *Dig Dis Sci*. 1986;31(5):468–475.
- de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. *Gastroenterology*. 1992;103(5):1630–1635.
- Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. *Liver Int*. 2012;32(9):1407–1414.
- Di Pascoli M, Ceranto E, De Nardi P, et al. Hospitalizations due to cirrhosis: clinical aspects in a large cohort of Italian patients and cost analysis report. *Dig Dis*. 2017;35(5):433–438.
- Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int*. 2009;29(5):629–635.
- Bajaj JS, Córdoba J, Mullen KD, et al. The design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. *Aliment Pharmacol Ther*. 2011;33(7):739–747.
- Sharma P. Minimal hepatic encephalopathy. *J Assoc Phys India*. 2009;57:760–763.
- Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. *Metab Brain Dis*. 2011;26(2):135–139.
- Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. *Hepatol Res*. 2014;44(10):E92–E99.
- Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dölle W. Latent portosystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. *Dig Dis Sci*. 1981;26(7):622–630.
- Kircheis G, Knoche A, Hilger N, et al. Hepatic encephalopathy and fitness to drive. *Gastroenterology*. 2009;137(5):1706–1715.
- Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. *Hepatology*. 1998;28(1):45–49.
- Roman E, Córdoba J, Torrens M, et al. Minimal hepatic encephalopathy is associated with falls. *Am J Gastroenterol*. 2011;106(3):476–482.
- Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. *Liver Transplant*. 2009;15(2):184–192.
- Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. *J Hepatol*. 1999;30(5):890–895.
- D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol*. 2006;44(1):217–231.
- Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. *Liver Transplant*. 2007;13(10):1366–1371.
- Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. The clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. *Hepatology*. 2010;51(5):1675–1682.
- Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. *Am J Gastroenterol*. 2011;106(9):1646–1653.
- Poordad FF. Review article: the burden of hepatic encephalopathy. *Aliment Pharmacol Ther*. 2007;25(suppl 1):3–9.
- Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. *Clin Gastroenterol Hepatol*. 2012;10(9):1034–1041.
- Chou R, Baker WL, Bañez LL, et al. Agency for Healthcare Research and Quality Evidence-based Practice Center methods provide guidance on prioritization and selection of harms in systematic reviews. *J Clin Epidemiol*. 2018;98:98–104.
- Craig JC, Irwig LM, Stockler MR. Evidence-based medicine: useful tools for decision making. *Med J Aust*. 2001;174(5):248–253.
- Tanjong-Ghogomu E, Tugwell P, Welch V. Evidence-based medicine and the cochrane collaboration. *Bull NYU Hosp Jt Dis*. 2009;67(2):198–205.

29. Altman DG, Moher D, Schulz KF. Improving the reporting of randomised trials: the CONSORT Statement and beyond. *Stat Med*. 2012;31(25):2985–2997.
30. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. *Syst Rev*. 2012;1:60.
31. Page MJ, Higgins JP, Clayton G, Sterne JA, Hróbjartsson A, Savović J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. *PLoS One*. 2016;11(7):e0159267.
32. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008;336(7644):601–605.
33. Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. *Aliment Pharmacol Ther*. 2012;36(7):619–626.
34. Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. *J Gastroenterol Hepatol*. 2015;30(2):236–243.
35. Dombrowsky T, Kristensen Mé, Rysgaard S, Gluud LL, Novovic S. Risk factors for and impact of respiratory failure on mortality in the early phase of acute pancreatitis. *Pancreatol*. 2016;16(5):756–760.
36. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. *Stat Med*. 2012;31(25):2973–2984.
37. Butterworth RF. Hepatic encephalopathy. *Alcohol Res Health*. 2003;27(3):240–246.
38. Butterworth RF. Hepatic encephalopathy in alcoholic cirrhosis. *Handb Clin Neurol*. 2014;125:589–602.
39. Mullen KD, Amodio P, Morgan MY. Therapeutic studies in hepatic encephalopathy. *Metab Brain Dis*. 2007;22(3–4):407–423.
40. Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. *Metab Brain Dis*. 2004;19(3–4):281–312.
41. Morgan MY. Hepatic encephalopathy in patients with cirrhosis. In: Dooley JS, Lok ASF, Garcia-Tsao G, Pinzani M, eds. *Sherlock's Diseases of the Liver and Biliary System*. 13th ed. Oxford: Wiley-Blackwell; 2018:151–179.
42. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. *Gastroenterology*. 1977;72(4 Pt 1):573–583.
43. Parsons-Smith BG, Summerskill WHJ, Dawson AM, Sherlock S. The electroencephalograph in liver disease. *Lancet*. 1957;2(7001):867–871.
44. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. *Lancet*. 1974;2(7872):81–84.
45. Montagnese S, Balistreri E, Schiff S, et al. Covert hepatic encephalopathy: agreement and predictive validity of different indices. *World J Gastroenterol*. 2014;20(42):15756–15762.
46. Zacharias HD, Jackson CD, Morgan MY, Olesen SS. Letter: step-wise diagnosis in covert hepatic encephalopathy - critical flicker frequency and MELD-score as a first-step approach. Replication and pitfalls. *Aliment Pharmacol Ther*. 2017;45(1):187–189.
47. Schomerus H, Hamster W. Neuropsychological aspects of portal-systemic encephalopathy. *Metab Brain Dis*. 1998;13(4):361–377.
48. Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. *J Hepatol*. 2001;34(5):768–773.
49. Morgan MY, Amodio P, Cook NA, et al. Qualifying and quantifying minimal hepatic encephalopathy. *Metab Brain Dis*. 2016;31(6):1217–1229.
50. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Häussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. *Hepatology*. 2002;35(2):357–366.
51. Kircheis G, Bode JG, Hilger N, Kramer T, Schnitzler A, Häussinger D. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. *Eur J Gastroenterol Hepatol*. 2009;21(12):1383–1394.
52. Ampuero J, Simón M, Montoliú C, et al. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. *Gastroenterology*. 2015;149(6):1483–1489.
53. Torlot FJ, McPhail MJ, Taylor-Robinson SD. Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. *Aliment Pharmacol Ther*. 2013;37(5):527–536.
54. Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. *Gastroenterology*. 2008;135(5):1591–1600.
55. Amodio P, Ridola L, Schiff S, et al. Improving detection of minimal hepatic encephalopathy using the inhibitory control task. *Gastroenterology*. 2010;139(2):510–518.
56. Sharma P, Kumar A, Singh S, Tyagi P, Kumar A. Inhibitory control test, critical flicker frequency, and psychometric tests in the diagnosis of minimal hepatic encephalopathy in cirrhosis. *Saudi J Gastroenterol*. 2013;19(1):40–44.
57. Allampati S, Duarte-Rojo A, Thacker LR, et al. Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicenter US-Based, norm-based study. *Am J Gastroenterol*. 2016;111(1):78–86.
58. Montagnese S, Schiff S, Turco M, et al. Simple tools for complex syndromes: a three-level difficulty test for hepatic encephalopathy. *Dig Liver Dis*. 2012;44(11):957–960.
59. Guérit J-M, Amantini A, Fischer C, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int*. 2009;29(6):789–796.
60. Kaplan PW. The EEG in metabolic encephalopathy and coma. *J Clin Neurophysiol*. 2004;21(5):307–318.
61. Jackson CD, Gram M, Halliday E, et al. New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy. *Clin Neurophysiol*. 2016;127(8):2933–2941.
62. Schiff S, Casa M, Di Caro V, et al. A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. *Hepatology*. 2016;63:1651–1659.
63. Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. *Cochrane Database Syst Rev*. 2018;5. CD012410.
64. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. *Cochrane Database Syst Rev*. 2016;5. Cd003044.
65. International Conference on Harmonisation Expert Working Group. *International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines*. vol. 1. Philadelphia (PA): Barnett International/PAREXEL; 1997.
66. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. *Med Care*. 1981;19(8):787–805.
67. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30(6):473–483.

68. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. *Gut*. 1999;45(2):295–300.
69. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3): 199–208.
70. De Angelis C, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. *Lancet*. 2005;365(9474):1827–1829.
71. ICMJE. *Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals*; December 2017. Available at: www.icmje.org/icmje-recommendations.pdf.
72. Wildt S, Krag A, Gluud L. Characteristics of randomised trials on diseases in the digestive system registered in ClinicalTrials.gov: a retrospective analysis. *BMJ Open*. 2011;1(2). e000309.
73. Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. *J Clin Epidemiol*. 2016;75:100–107.